TAP EN Article Feed

FDA Approves Atezolizumab for Adjuvant Treatment of MRD-Positive Muscle-Invasive Bladder Cancer

The ASCO Post — Thu, 11 Jun 2026 02:36:12 +00:00

In May, the FDA approved the PD-L1 inhbitor atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as adjuvant therapies for adults with MIBC after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD), as determined by an FDA-authorized test.

Can AI Provide an ‘Early Alert’ for Breast Cancer Before Diagnosis?

The ASCO Post — Thu, 11 Jun 2026 05:57:44 +00:00

Three commercially available radiology artificial intelligence (AI) systems have shown the potential to flag early signs of breast cancer up to 6 years before a diagnosis, according to the results of a Swedish study.

Perioperative Serplulimab in PD-L1–Positive Gastric Cancer

The ASCO Post — Thu, 11 Jun 2026 02:18:28 +00:00

In a Chinese phase III study (ASTRUM-006), neoadjuvant serplulimab plus S-1/oxaliplatin (SOX) followed by adjuvant serplulimab improved event-free survival vs neoadjuvant and adjuvant SOX in patients with PD-L1–positive, resectable gastric or gastroesophageal junction adenocarcinoma.

Urologic Surgeon Sworn in as AMA President

The ASCO Post — Thu, 11 Jun 2026 05:46:11 +00:00

He brings more than 25 years of urologic surgery experience to the role, including 15 years specializing in robotic urologic oncology procedures. As only the second urologist and third Black physician overall to serve as AMA President, he is committed to advancing patient-centered care and addressing longstanding health disparities through improved access, prevention, and coordinated care.

Head and Neck Cancer: HPV-DeepSeek May Identify Earlier Signs of Postoperative Recurrence

The ASCO Post — Thu, 11 Jun 2026 03:30:28 +00:00

Researchers clinically validated a sensitive blood test as a whole-genome sequencing assay for detecting circulating tumor human papillomavirus (HPV) DNA in patients with HPV-associated head and neck cancer after surgery to search for residual disease as a sign of potential recurrence.

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

The ASCO Post — Thu, 11 Jun 2026 02:37:20 +00:00

Results from the randomized phase III KEYNOTE-B15/EV-304 study show that neoadjuvant and adjuvant enfortumab vedotin-ejfv plus pembrolizumab significantly improved event-free survival, overall survival, and pathologic complete response rate in patients with MIBC who were eligible for cisplatin-based chemotherapy.

Better Together: The Case for True Physician-AP Partnership in Oncology

The ASCO Post — Thu, 11 Jun 2026 02:13:01 +00:00

“At 8 am, the infusion chairs are already full. The oncologist is in a room seeing a new patient consult, the pharmacist is adjusting doses based on new lab values, and the advanced practitioner (AP) is sitting with a patient—reviewing symptoms, discussing how to manage treatment side effects, and helping determine whether treatment should proceed that day. This scene plays out daily in oncology practices across the country and reflects a reality many physicians know well: modern cancer care is a team effort, and APs are central to this scenario.”